67 related articles for article (PubMed ID: 8457238)
21. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
[TBL] [Abstract][Full Text] [Related]
22. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment.
El-Kamel AH; Abdel-Aziz AA; Fatani AJ; El-Subbagh HI
Int J Pharm; 2008 Jun; 358(1-2):248-55. PubMed ID: 18502065
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
Prueksaritanont T; Gorham LM; Breslin MJ; Hutchinson JH; Hartman GD; Vyas KP; Baillie TA
Drug Metab Dispos; 1997 Aug; 25(8):978-84. PubMed ID: 9280406
[TBL] [Abstract][Full Text] [Related]
25. In vitro stability and in vivo pharmacokinetic studies of a model opioid peptide, H-Tyr-D-Ala-Gly-Phe-D-Leu-OH (DADLE), and its cyclic prodrugs.
Yang JZ; Chen W; Borchardt RT
J Pharmacol Exp Ther; 2002 Nov; 303(2):840-8. PubMed ID: 12388671
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of 9-nitro-20(S)-camptothecin in rats.
Zhong DF; Li K; Xu JH; Du Y; Zhang YF
Acta Pharmacol Sin; 2003 Mar; 24(3):256-62. PubMed ID: 12617776
[TBL] [Abstract][Full Text] [Related]
27. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
[TBL] [Abstract][Full Text] [Related]
28. [Tissue distribution and excretion of 5-fluorouracil from indomethacin 5-fluorouracil-1-ylmethylester in rats].
Wang GH; Wang J; Qi W; Chen Y; Sun LX
Yao Xue Xue Bao; 2008 Jan; 43(1):81-5. PubMed ID: 18357738
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and bioavailability of nimesulide in goats.
Rao GS; Malik JK; Siddaraju VB; Shankaramurthy NC
J Vet Pharmacol Ther; 2007 Apr; 30(2):157-62. PubMed ID: 17348902
[TBL] [Abstract][Full Text] [Related]
30. [A bioequivalence study in man of tablet and capsule formulations of the nonsteroidal anti-inflammatory compound 2-methoxyphenyl 1-methyl-5-(p-methylbenzoylpyrrol)-2-acetamidoacetate].
Annunziato L; di Renzo G
Clin Ter; 1993 Jan; 142(1 Pt 2):3-10. PubMed ID: 8472519
[TBL] [Abstract][Full Text] [Related]
31. Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the rat.
Carini M; Aldini G; Orioli M; Piccoli A; Rossoni G; Maffei Facino R
Life Sci; 2004 May; 74(26):3291-305. PubMed ID: 15094329
[TBL] [Abstract][Full Text] [Related]
32. Species and organ differences in first-pass metabolism of the ester prodrug L-751,164 in dogs and monkeys. In vivo and in vitro studies.
Prueksaritanont T; Gorham LM; Ellis JD; Fernandez-Metzler C; Deluna P; Gehret JR; Strong KL; Hochman JH; Askew BC; Duggan ME; Gilbert JD; Lin JH; Vyas KP
Drug Metab Dispos; 1996 Nov; 24(11):1263-71. PubMed ID: 8937862
[TBL] [Abstract][Full Text] [Related]
33. In vivo/in vitro correlations for four differently dissolving ketorolac tablets.
Gordon MS; Chowhan Z
Biopharm Drug Dispos; 1996 Aug; 17(6):481-92. PubMed ID: 8866039
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of salicin as an antipyretic prodrug that does not cause gastric injury.
Akao T; Yoshino T; Kobashi K; Hattori M
Planta Med; 2002 Aug; 68(8):714-8. PubMed ID: 12221594
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma.
Xu W; Sun J; Zhang TT; Ma B; Cui SM; Chen DW; He ZG
Acta Pharmacol Sin; 2006 Dec; 27(12):1642-6. PubMed ID: 17112421
[TBL] [Abstract][Full Text] [Related]
36. Stereospecific pharmacokinetics and toxicodynamics of ketorolac after oral administration of the racemate and optically pure enantiomers to the rat.
Jamali F; Lovlin R; Corrigan BW; Davies NM; Aberg G
Chirality; 1999; 11(3):201-5. PubMed ID: 10079499
[TBL] [Abstract][Full Text] [Related]
37. Aminocarbonyloxymethyl ester prodrugs of flufenamic acid and diclofenac: suppressing the rearrangement pathway in aqueous media.
Ribeiro L; Silva N; Iley J; Rautio J; Järvinen T; Mota-Filipe H; Moreira R; Mendes E
Arch Pharm (Weinheim); 2007 Jan; 340(1):32-40. PubMed ID: 17206608
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/antifungal drug DB75 (2,5-bis(4-guanylphenyl)furan dihydrochloride).
Midgley I; Fitzpatrick K; Taylor LM; Houchen TL; Henderson SJ; Wright SJ; Cybulski ZR; John BA; McBurney A; Boykin DW; Trendler KL
Drug Metab Dispos; 2007 Jun; 35(6):955-67. PubMed ID: 17360833
[TBL] [Abstract][Full Text] [Related]
40. Bioavailability study of furosemide prodrugs in rats.
Prandi C; Fagiolino P; Manta E; Dominguez Llera L
Farmaco; 1992 Sep; 47(9):1225-34. PubMed ID: 1300128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
